Back to Search
Start Over
Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients
- Source :
-
Journal of Neuroimmunology . Nov2006, Vol. 180 Issue 1/2, p63-70. 8p. - Publication Year :
- 2006
-
Abstract
- Abstract: Effects of B cell depletion by rituximab, a monoclonal antibody to CD20, were studied in patients with relapsing MS that had not responded optimally to standard immunomodulatory therapies. Flow cytometry demonstrated reduced cerebrospinal fluid (CSF) B cells and T cells in most patients at 6 months post-treatment. ELISAs demonstrated modest reductions in serum antibodies to myelin oligodendrocyte glycoprotein and myelin basic protein in some subjects. Beta-interferon neutralizing antibodies were reduced in three subjects, but developed anew after treatment in three others, suggesting caution in considering rituximab as a means to eliminate NABs. In summary, rituximab depleted B cells from CSF at 24 weeks after initial treatment, and this B cell depletion was associated with a reduction in CSF T cells as well. [Copyright &y& Elsevier]
- Subjects :
- *B cells
*LEUCOCYTES
*AUTOANTIBODIES
*ANTINEOPLASTIC agents
Subjects
Details
- Language :
- English
- ISSN :
- 01655728
- Volume :
- 180
- Issue :
- 1/2
- Database :
- Academic Search Index
- Journal :
- Journal of Neuroimmunology
- Publication Type :
- Academic Journal
- Accession number :
- 23048619
- Full Text :
- https://doi.org/10.1016/j.jneuroim.2006.06.029